BTMD
ACHAT TOTAL: 131 950 titres (~202 203,50 $ US)
- Insiders
- Beer Marc D
- Total bought
- $202,204
- Total sold
- —
- Last activity
- 2026-08-11
- Last synced
-
2026-08-21 23:36:53
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Neutral signal Scored 2026-08-14
BTMD shows a genuine operational turnaround with improving margins and strong FCF generation, supported by a meaningful insider cluster buy of 131,950 shares — a classically bullish event-driven signal.
The first sentence of the analysis written for BTMD on 2026-08-14 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 71.5% | 70.5% | 68.8% | 66.9% | 65.0% | |
| Ebit Margin | 25.3% | 6.1% | 20.9% | 3.5% | 24.8% | |
| Ebitda Margin | 27.2% | 7.9% | 21.3% | 4.8% | 25.8% | |
| Operating Profit Margin | 18.5% | 16.0% | 15.5% | -36.8% | 24.8% | |
| Pretax Profit Margin | 19.6% | 0.5% | -0.1% | 1.0% | 23.6% | |
| Continuous Operations Profit Margin | 16.4% | 0.0% | -1.5% | 0.8% | 23.4% | |
| Net Profit Margin | 14.1% | 1.6% | 1.8% | -0.6% | 23.4% | |
| Bottom Line Profit Margin | 14.1% | 1.6% | 1.8% | -0.6% | 23.4% | |
| Current Ratio | 1.215 | 1.322 | 5.507 | 5.392 | 2.720 | |
| Quick Ratio | 0.791 | 1.034 | 4.728 | 4.796 | 2.164 | |
| Solvency Ratio | 0.194 | 0.030 | 0.021 | 0.007 | 0.678 | |
| Cash Ratio | 0.536 | 0.764 | 4.006 | 4.222 | 1.546 | |
| Price To Earnings Ratio | 3.023 | 67.101 | 38.000 | -31.083 | 2.274 | |
| Price To Earnings Growth Ratio | 0.004 | -2.302 | -0.182 | 0.302 | 0.190 | |
| Forward Price To Earnings Growth Ratio | 0.004 | -2.302 | -0.182 | 0.302 | 0.190 | |
| Price To Earnings Diluted Ratio | 3.514 | 67.101 | 38.000 | -31.083 | 2.274 | |
| Price To Earnings Diluted Growth Ratio | 0.005 | -2.302 | -0.182 | 0.302 | 0.190 | |
| Price To Book Ratio | -1.389 | -1.999 | -4.320 | -0.676 | 17.995 | |
| Price To Sales Ratio | 0.423 | 1.074 | 0.685 | 0.182 | 0.532 | |
| Price To Free Cash Flow Ratio | 2.695 | 5.457 | 5.255 | -2.734 | 2.481 | |
| Price To Operating Cash Flow Ratio | 2.311 | 4.681 | 4.724 | -3.283 | 2.201 | |
| Debt To Assets Ratio | 1.021 | 0.906 | 0.740 | 1.079 | 0.687 | |
| Debt To Equity Ratio | -1.878 | -1.047 | -3.908 | -2.709 | 9.052 | |
| Debt To Capital Ratio | 2.139 | 22.469 | 1.344 | 1.585 | 0.901 | |
| Long Term Debt To Capital Ratio | 2.386 | -21.400 | 1.381 | 1.657 | 0.886 | |
| Financial Leverage Ratio | -1.838 | -1.155 | -5.283 | -2.511 | 13.171 | |
| Working Capital Turnover Ratio | 14.622 | 3.378 | 2.031 | 2.941 | 6.076 | |
| Operating Cash Flow Ratio | 0.782 | 0.878 | 1.210 | -0.488 | 1.948 | |
| Operating Cash Flow Sales Ratio | 0.183 | 0.229 | 0.145 | -0.056 | 0.242 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.858 | 0.858 | 0.899 | 1.201 | 0.887 | |
| Debt Service Coverage Ratio | 2.686 | 0.848 | 2.922 | 0.735 | 5.349 | |
| Interest Coverage Ratio | 3.243 | 2.873 | 4.504 | -15.004 | 20.658 | |
| Short Term Operating Cash Flow Coverage Ratio | 5.631 | 7.239 | 4.301 | -1.465 | 6.744 | |
| Operating Cash Flow Coverage Ratio | 0.320 | 0.408 | 0.234 | -0.076 | 0.903 | |
| Capital Expenditure Coverage Ratio | 7.018 | 7.036 | 9.909 | -4.982 | 8.857 | |
| Dividend Paid And Capex Coverage Ratio | 5.220 | 4.049 | 2.357 | -0.622 | 2.217 | |
| Dividend Payout Ratio | 0.064 | 1.503 | 2.622 | -13.298 | 0.350 | |
| Enterprise Value Multiple | 3.201 | 18.172 | 3.866 | 8.954 | 2.357 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 71.5% | ▲0.9% | ▲2.9% |
| Ebit Margin | 25.3% | ▲19.2% | ▲9.2% |
| Ebitda Margin | 27.2% | ▲19.3% | ▲9.8% |
| Operating Profit Margin | 18.5% | ▲2.5% | ▲10.9% |
| Pretax Profit Margin | 19.6% | ▲19.0% | ▲10.6% |
| Continuous Operations Profit Margin | 16.4% | ▲16.4% | ▲8.6% |
| Net Profit Margin | 14.1% | ▲12.5% | ▲6.0% |
| Bottom Line Profit Margin | 14.1% | ▲12.5% | ▲6.0% |
| Current Ratio | 1.215 | ▼-0.107 | ▼-2.016 |
| Quick Ratio | 0.791 | ▼-0.243 | ▼-1.911 |
| Solvency Ratio | 0.194 | ▲0.164 | ▲0.008 |
| Cash Ratio | 0.536 | ▼-0.228 | ▼-1.679 |
| Price To Earnings Ratio | 3.023 | ▼-64.078 | ▼-12.840 |
| Price To Earnings Growth Ratio | 0.004 | ▲2.305 | ▲0.401 |
| Forward Price To Earnings Growth Ratio | 0.004 | ▲2.305 | ▲0.401 |
| Price To Earnings Diluted Ratio | 3.514 | ▼-63.587 | ▼-12.447 |
| Price To Earnings Diluted Growth Ratio | 0.005 | ▲2.307 | ▲0.402 |
| Price To Book Ratio | -1.389 | ▲0.610 | ▼-3.311 |
| Price To Sales Ratio | 0.423 | ▼-0.651 | ▼-0.156 |
| Price To Free Cash Flow Ratio | 2.695 | ▼-2.762 | ▲0.064 |
| Price To Operating Cash Flow Ratio | 2.311 | ▼-2.370 | ▲0.184 |
| Debt To Assets Ratio | 1.022 | ▲0.116 | ▲0.135 |
| Debt To Equity Ratio | -1.878 | ▼-0.831 | ▼-1.780 |
| Debt To Capital Ratio | 2.139 | ▼-20.330 | ▼-3.548 |
| Long Term Debt To Capital Ratio | 2.386 | ▲23.785 | ▲5.404 |
| Financial Leverage Ratio | -1.838 | ▼-0.683 | ▼-2.315 |
| Working Capital Turnover Ratio | 14.622 | ▲11.244 | ▲8.812 |
| Operating Cash Flow Ratio | 0.782 | ▼-0.096 | ▼-0.084 |
| Operating Cash Flow Sales Ratio | 0.183 | ▼-0.046 | ▲0.034 |
| Free Cash Flow Operating Cash Flow Ratio | 0.858 | ▼-0.000 | ▼-0.083 |
| Debt Service Coverage Ratio | 2.686 | ▲1.838 | ▲0.178 |
| Interest Coverage Ratio | 3.243 | ▲0.370 | ▼-0.011 |
| Short Term Operating Cash Flow Coverage Ratio | 5.631 | ▼-1.608 | ▲1.141 |
| Operating Cash Flow Coverage Ratio | 0.320 | ▼-0.088 | ▼-0.038 |
| Capital Expenditure Coverage Ratio | 7.018 | ▼-0.018 | ▲1.450 |
| Dividend Paid And Capex Coverage Ratio | 5.220 | ▲1.171 | ▲2.576 |
| Dividend Payout Ratio | 0.064 | ▼-1.439 | ▲1.816 |
| Enterprise Value Multiple | 3.201 | ▼-14.971 | ▼-4.109 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $81.3M | $211.8M | $127.0M | $30.1M | $74.2M | |
| Enterprise value | $167.1M | $283.3M | $152.9M | $71.3M | $84.8M | |
| EV / Sales | 0.87x | 1.44x | 0.82x | 0.43x | 0.61x | |
| EV / Op. cash flow | 4.75x | 6.26x | 5.69x | -7.78x | 2.52x | |
| EV / Free cash flow | 5.54x | 7.30x | 6.33x | -6.48x | 2.83x | |
| EV / EBITDA | 3.20x | 18.17x | 3.87x | 8.95x | 2.36x | |
| Net debt / EBITDA | 1.64x | 4.59x | 0.65x | 5.18x | 0.29x | |
| Current ratio | 1.22x | 1.32x | 5.51x | 5.39x | 2.72x | |
| Income quality | 1.30x | 983.54x | 8.11x | -6.92x | 1.03x | |
| Graham number | — | — | — | — | $7 | |
| Graham net-net | -$4 | -$5 | -$3 | -$10 | -$2 | |
| Tax burden | 72.0% | 310.7% | -2695.9% | -56.6% | 99.1% | |
| Interest burden | 77.4% | 8.5% | -0.3% | 29.7% | 95.2% | |
| Working capital | $9.7M | $16.6M | $100.1M | $82.4M | $29.8M | |
| Invested capital | $33.2M | $42.0M | $108.2M | $91.0M | $37.0M | |
| Return on assets | 25.1% | 2.6% | 2.1% | -0.9% | 60.0% | |
| Operating ROA | 30.9% | 22.8% | 21.5% | -73.2% | 79.5% | |
| Return on tangible assets | 27.7% | 2.9% | 2.2% | -0.9% | 65.5% | |
| Return on equity | -46.2% | -3.0% | -11.3% | 2.2% | 790.8% | |
| Return on invested capital | 43.0% | 1.8% | 20.5% | -47.3% | 81.1% | |
| Return on capital employed | 56.8% | 44.6% | 21.5% | -65.4% | 93.4% | |
| Earnings yield | 33.3% | 1.5% | 2.6% | -3.2% | 43.9% | |
| Free cash flow yield | 37.1% | 18.3% | 19.0% | -36.6% | 40.3% | |
| Capex / Op. cash flow | 14.2% | 14.2% | 10.1% | -20.1% | 11.3% | |
| Capex / Depreciation | 136.6% | 179.9% | 90.6% | 83.6% | 271.9% | |
| Capex / Sales | 2.6% | 3.3% | 1.5% | 1.1% | 2.7% | |
| SG&A / Sales | 53.0% | 54.5% | 53.3% | 103.7% | 38.7% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 4.6% | 4.4% | 4.9% | 49.8% | 0.0% | |
| Intangibles / Total assets | 9.4% | 12.4% | 3.2% | 4.5% | 8.4% | |
| Days sales outstanding | 15d | 14d | 16d | 15d | 14d | |
| Days payables outstanding | 45d | 36d | 26d | 28d | 33d | |
| Operating cycle | 141d | 107d | 125d | 90d | 86d | |
| Cash conversion cycle | 96d | 71d | 99d | 63d | 53d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▼-61.6%EV / Sales ▼-39.5%EV / EBITDA ▼-82.4%EV / Op. cash flow ▼-1.513Earnings yield ▲+0.318
Profitability
Return on equity ▼-0.432Return on assets ▲+0.226Return on invested capital ▲+0.412Return on capital employed ▲+0.122Operating ROA ▲+0.081Income quality ▼-982.242Tax burden ▼-2.388
Efficiency
Days sales outstanding ▲+0.321Days payables outstanding ▲+8.917Operating cycle ▲+33.952Cash conversion cycle ▲+25.035Capex / Sales ▼-0.007R&D / Sales n/a
Balance-sheet strength
Current ratio ▼-0.107Net debt / EBITDA ▼-2.944Working capital ▼-6934000.000Invested capital ▼-8810000.000Intangibles / Total assets ▼-0.030
Change over 5 years
Valuation
Market cap ▲+9.6%EV / Sales ▲+42.9%EV / EBITDA ▲+35.8%EV / Op. cash flow ▲+2.234Earnings yield ▼-0.107
Profitability
Return on equity ▼-8.370Return on assets ▼-0.349Return on invested capital ▼-0.380Return on capital employed ▼-0.366Operating ROA ▼-0.486Income quality ▲+0.268Tax burden ▼-0.272
Efficiency
Days sales outstanding ▲+0.881Days payables outstanding ▲+12.900Operating cycle ▲+55.833Cash conversion cycle ▲+42.933Capex / Sales ▼-0.001R&D / Sales n/a
Balance-sheet strength
Current ratio ▼-1.505Net debt / EBITDA ▲+1.349Working capital ▼-20093000.000Invested capital ▼-3785000.000Intangibles / Total assets ▲+0.010
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-08-06 biote Corp. (BTMD) Q2 2026 Earnings Call Transcript biote Corp. (BTMD) Q2 2026 Earnings Call Transcript
- 2026-08-05 biote Corp. (BTMD) Reports Break-Even Earnings for Q2 biote Corp. (BTMD) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of $0.03. This compares to earnings of $0.1 per share a year ago.
- 2026-08-05 biote Q2 Earnings Call Highlights biote NASDAQ: BTMD reported lower second-quarter revenue and a net loss as a voluntary recall of certain hormone pellets supplied by Asteria Health disrupted procedure volumes, while management said supply conditions have since normalized and should support sequential improvement in the second half of 2026.
- 2026-08-05 Biote Reports Second Quarter 2026 Financial Results IRVING, Texas--(BUSINESS WIRE)--Biote (NASDAQ: BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our practitioners'' patients, today announced financial results for the second quarter ended June 30, 2026. “Over the past year Biote has achieved meaningful progress in advancing our strategic initiatives, driving fundamental improvements that we believe position the Company to achieve sustainable procedure revenue growth,” said Bob Peterso.
- 2026-07-22 Biote Schedules Second Quarter 2026 Financial Results Release and Conference Call IRVING, Texas--(BUSINESS WIRE)--biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our Practitioners'' patients, today announced the Company will provide second quarter financial results on Wednesday, August 5, 2026, after the close of the market. A conference call to discuss the firm''s results will be held at 5:00 p.m. ET the same day. Conference Call Details The conference call may be acc.
- 2026-06-01 Biote Appoints Komal Bajaj, MD, MS as Chief Medical Officer IRVING, Texas--(BUSINESS WIRE)--Biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”) today announced the appointment of Komal Bajaj, MD, MS, as Chief Medical Officer, effective June 1, 2026. Dr. Bajaj is a nationally recognized physician executive, board-certified OB/GYN and reproductive geneticist with more than two decades of experience spanning clinical practice, healthcare quality, academic medicine, innovation, and systems leadership. She joins Biote following senior leadership roles with.
- 2026-05-28 Biote Names Bob Peterson, Current Chief Financial and Chief Business Officer, as Interim CEO [url="]Biote[/url] (NASDAQ: BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our practitioners'' pa
- 2026-05-28 Biote Names Bob Peterson, Current Chief Financial and Chief Business Officer, as Interim CEO IRVING, Texas--(BUSINESS WIRE)--Biote (NASDAQ: BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our practitioners'' patients, today announced that Bob Peterson, Chief Financial Officer and Chief Business Officer, has been named Interim Chief Executive Officer and Director, effective June 8, 2026. Bret Christensen is stepping down from his role as Chief Executive Officer and will continue to serve on the Company''s Board of Directors. In.